We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Technology Accurately Predicts Breast Cancer Risk Via ‘Zombie Cells’

By LabMedica International staff writers
Posted on 30 Sep 2024

Breast cancer remains one of the most common cancers worldwide, causing 670,000 deaths in 2022. More...

A key aspect of assessing cancer risk involves identifying dying cells. A new study has demonstrated that artificial intelligence (AI) can enhance treatment for women by identifying irregular-looking cells, thus improving cancer risk assessment. The study, published in The Lancet Digital Health, found that AI significantly outperformed current clinical benchmarks for breast cancer risk prediction.

Researchers from the University of Copenhagen (Copenhagen, Denmark) used deep learning AI technology to analyze mammary tissue biopsies from donors, searching for signs of cell damage, a marker of cancer risk. This damage is linked to cellular senescence, where cells stop dividing but remain metabolically active. While senescent cells can help suppress cancer development, they can also trigger inflammation, which may lead to tumor formation. By using AI to detect these senescent cells in tissue samples, the researchers were able to predict breast cancer risk more effectively than the Gail model, the current standard for risk assessment.

To train the AI, the researchers used cells in a lab that were intentionally damaged to induce senescence. The AI was then applied to donor biopsies to detect senescent cells—often called "zombie cells" because they have lost some functions but are not entirely dead. These cells are closely associated with cancer development, so the AI algorithm was designed to predict senescence by analyzing the irregular shapes of cell nuclei, which change as the cells become senescent. The study also found that combining two AI models or integrating an AI model with the Gail score, greatly improved cancer risk predictions. One combination produced an odds ratio of 4.70, indicating that donors with certain cell features had nearly five times the risk of developing cancer in the coming years. While it will take time before this technology is available in clinical settings, its potential is global. Since the method only requires standard tissue sample images, it could eventually be used worldwide, offering women better insights for treatment decisions.

“The algorithm is a great leap forward in our ability to identify these cells. Millions of biopsies are taken every year, and this technology can help us better identify risks and give women better treatment,” said Associate Professor Morten Scheibye-Knudsen from the Department of Cellular and Molecular Medicine and senior author of the study. “We will be able use this information to stratify patients by risk and improve treatment and screening protocols. Doctors can keep a closer eye on high-risk individuals, they can undergo more frequent mammograms and biopsies, and we can potentially catch cancer earlier. At the same time, we can reduce the burden for low-risk individuals, e.g. by taking biopsies less frequently.”

Related Links:
University of Copenhagen


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Figure 1 from Lim J, et al. “Amplification of RNA for Identification of Zika and HCV in Whole Blood.” Science Advances, 2026. https://doi.org/10.1126/sciadv.aeb6129. Licensed under CC BY-NC 4.0. Created in BioRender: https://BioRender.com/mr4p5qy.

Portable Test Detects Zika and Hepatitis C RNA from Whole Blood

Timely detection of Zika virus and hepatitis C is essential, but conventional testing often relies on centralized laboratories and complex sample processing. In regions with limited medical infrastructure,... Read more

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: Melioidosis is a serious, sometimes fatal infection caused by Burkholderia pseudomallei, a bacterium found in tropical and subtropical soil and surface water. (Image Credit: Adobe Stock)

Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions

Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Industry

view channel
Image: Siemens Healthineers has begun carving out its in vitro diagnostics business as a standalone company named Olyrian Diagnostics (Photo courtesy of Siemens Healthineers)

Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business

Siemens Healthineers has begun carving out its in vitro diagnostics business, which will operate as Olyrian Diagnostics. The new name will be introduced in stages as the business prepares to become a standalone... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.